Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genentech Licenses Afraxis’ Therapies

by Rick Mullin
February 4, 2013 | A version of this story appeared in Volume 91, Issue 5

Genentech has signed a licensing deal with Afraxis that gives the Roche subsidiary exclusive worldwide rights to an unspecified portfolio of therapies that Afraxis has under development. Afraxis is best known for its work on Fragile X, a target in autism. Under the deal, Genentech would pay as much as $187 million, including an undisclosed up-front payment and milestone payments. Founded and currently owned by Avalon Ventures, a San Diego venture capital firm, Afraxis is five years old.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.